MedPath

A Clinical Trial To Check The Efficacy Of Karkashchadadi Kwath In Medodushti (Dyslipidemia)

Phase 2
Conditions
Health Condition 1: E785- Hyperlipidemia, unspecified
Registration Number
CTRI/2023/07/054923
Lead Sponsor
Shri Krishna Govt. Ayurvedic College and Hospital. Kurukshetra
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i. Patients willing to sign the consent form.

ii. Patients between the age group of 25-60 years of either sex.

iii. Patients having underweight, normal weight, overweight, and class I obesity according to BMI

iv. Diagnosed & confirmed cases of Medodushti (Dyslipidemia) & Medoroga on the basis of criteria

given by NCEP-ATPIII. (Borderline High category).

Exclusion Criteria

a) Patient not fulfilling inclusion criteria.

b) Patient not willing for clinical trial.

c) Patient below 25yrs of age group and above 65yrs of age group.

d) Patients having medical history of -

Unstable angina, Myocardial Infarction, Heart failure or stroke.

e) Uncontrolled Hypertension (Diastolic Blood Pressure > 100 mmHg).

f) Uncontrolled Diabetes Mellitus.

g) Impaired Renal Function (Creatinine > 2 mg/dl).

h) ALT and AST >3 times of upper limit of normal.

i) Patient on steroid therapy and oral contraceptive therapy.

j) Pregnant and lactating patient.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The effect of drug will be analyzed on 1st 15th 30th 45th 60th day & after treatment by the means of change in subjective criteria & objective criteria (body weight, BMI, CBC, Lipid profile , SGOT, SGPT, Serum creatinine , FBS, Urine Routine & Microscopy,Timepoint: Approximate 60days per patient
Secondary Outcome Measures
NameTimeMethod
1. To determine the effect of drug on clinical parameters & biochemical findings associated <br/ ><br>with Medodushti (Dyslipidemia). <br/ ><br>2. To advise preventive measures to check the occurrence of disease in individual and masses. <br/ ><br>3. To standardize the ayurvedic line of treatment, both drug and dose which may have effective <br/ ><br>role in management of patients of Medodushti (Dyslipidemia). <br/ ><br>4. To explain the Medodushti (Dyslipidemia) critical review on the basis of classical text of <br/ ><br>ayurveda and with the help of modern literature. <br/ ><br>5. To provide cheap, safe, and effective treatment from ayurveda to Dyslipidemic patients. <br/ ><br>6. To rule out secondary causes that count for lipoprotein disorder. <br/ ><br>7. To prevent the complication of Dyslipidemia like atherosclerosis, CAD, CVD & PVD. <br/ ><br>Timepoint: 2 year
© Copyright 2025. All Rights Reserved by MedPath